ALMS

Business Context and Reporting Period

Company: Alumis Inc. (ALMS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Alumis is a clinical-stage biopharmaceutical company focused on developing targeted therapies for autoimmune disorders. Its primary pipeline includes envudeucitinib (envu), a TYK2 inhibitor for psoriasis and systemic lupus erythematosus, and A-005, a CNS-penetrant TYK2 inhibitor. On May 21, 2025, the company completed the acquisition of ACELYRIN, Inc., adding the IGF-1R inhibitor lonigutamab to its portfolio.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Income vs. Loss: The company reported a net income of $59.3 million for the three months ended June 30, 2025, compared to a net loss of $56.5 million in the same period in 2024. This reversal was primarily driven by a non-cash gain on bargain purchase of $187.9 million recognized upon the completion of the ACELYRIN Merger.
• Revenue Growth: Total revenue for the six months ended June 30, 2025, was $20.1 million, compared to zero in the prior year period. This includes $17.4 million in license revenue and $2.7 million in collaboration revenue from a new agreement with Kaken Pharmaceutical Co., Ltd.
• Expense Increases: Operating expenses increased significantly due to the ACELYRIN acquisition and expanded clinical activities. Research and development (R&D) expenses rose to $205.4 million for the six months ended June 30, 2025, from $90.5 million in the prior year. General and administrative (G&A) expenses increased to $56.7 million from $13.2 million, driven by transaction costs and integration expenses.
• Balance Sheet Expansion: Total assets increased from $341.0 million at December 31, 2024, to $610.9 million at June 30, 2025, largely due to the acquisition of ACELYRIN's cash, marketable securities, and intangible assets (IPR&D).

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities of $486.3 million are sufficient to meet operating and capital requirements for at least 12 months from the filing date. The company expects to incur substantial losses for the foreseeable future and will need to raise additional capital.
• Strategic Initiatives: The company is advancing Phase 3 trials for envu in psoriasis (ONWARD program) and a Phase 2b trial in systemic lupus erythematosus. It is also evaluating the development of lonigutamab (acquired from ACELYRIN) for Thyroid Eye Disease.
• Key Risks:
  • Development Risk: No products are currently approved for sale; success depends on clinical trial outcomes and regulatory approvals.
  • Integration Risk: Risks associated with integrating ACELYRIN's operations and realizing anticipated synergies.
  • Legal Proceedings: The company assumed a pending securities class action lawsuit against ACELYRIN regarding disclosures related to a Phase 2b trial of izokibep. The outcome is uncertain and could result in significant costs.
  • Capital Requirements: Failure to secure additional financing could force the company to delay or scale back development programs.

Investor Verification Checklist

• Gain on Bargain Purchase: Verify the sustainability of the $187.9 million gain, which is a non-recurring, non-cash item resulting from the ACELYRIN acquisition accounting.
• Revenue Recognition: Review the terms of the Kaken collaboration agreement to understand the timing of future revenue recognition for the $20.0 million upfront payment and subsequent milestones.
• IPR&D Valuation: Assess the $51.0 million valuation of the acquired lonigutamab intangible asset and the assumptions used (e.g., discount rate, probability of success).
• Legal Exposure: Monitor the status of the pending securities class action lawsuit against ACELYRIN for potential financial impact.
• Cash Burn Rate: Analyze the $186.7 million net cash used in operating activities for the six-month period to gauge the runway provided by the $486.3 million liquidity position.